Literature DB >> 3348473

Geographic distribution of human immunodeficiency virus markers in parenteral drug abusers.

W R Lange1, F R Snyder, D Lozovsky, V Kaistha, M A Kaczaniuk, J H Jaffe.   

Abstract

Drug abuse treatment programs in six regions of the United States collaborated in a study aimed at monitoring trends in the seroprevalence of human immunodeficiency virus (HIV) antibodies. The wide disparities in HIV seroprevalence in the face of similarities in drug using behavior have important implications for prevention. In the New York City area (Harlem, Brooklyn), 61 per cent of samples (N = 280) obtained in late 1986 were positive, up from 50 per cent of samples (N = 585) in early 1985. In Baltimore, Maryland, 29 per cent of samples (N = 184) representing 11 programs were positive. In contrast, samples from programs distant from the Northeast corridor had far lower rates: Denver, Colorado 5 per cent (N = 100); San Antonio, Texas 2 per cent (N = 106); Southern California, 1.5 per cent (N = 413); and Tampa, Florida, 0 per cent (N = 102). Contrary to expectations, there was no corresponding difference in reported lifetime needle sharing experiences, which ranged from 70 per cent in New York to 99 per cent in San Antonio. HIV seropositivity was associated only with geographic location and ethnicity; however, because needle sharing is practiced by parenteral drug abusers in areas where seroprevalence is still relatively low, these areas are potentially vulnerable to the same catastrophic spread seen in the Northeast. A window of opportunity exists where prompt, vigorous, and aggressive efforts at prevention could have major impact.

Entities:  

Mesh:

Year:  1988        PMID: 3348473      PMCID: PMC1349372          DOI: 10.2105/ajph.78.4.443

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  9 in total

1.  The prevalence of HTLV-III/LAV antibodies among intravenous drug users attending treatment programs in California: a preliminary report.

Authors:  N Levy; J R Carlson; S Hinrichs; N Lerche; M Schenker; M B Gardner
Journal:  N Engl J Med       Date:  1986-02-13       Impact factor: 91.245

2.  AIDS and addiction in New York City.

Authors:  E Drucker
Journal:  Am J Drug Alcohol Abuse       Date:  1986       Impact factor: 3.829

3.  AIDS risk-group profiles in whites and members of minority groups.

Authors:  R Bakeman; J R Lumb; R E Jackson; D W Smith
Journal:  N Engl J Med       Date:  1986-07-17       Impact factor: 91.245

4.  Sharing of needles among users of intravenous drugs.

Authors:  J L Black; M P Dolan; H A DeFord; J A Rubenstein; W E Penk; R Robinowitz; J R Skinner
Journal:  N Engl J Med       Date:  1986-02-13       Impact factor: 91.245

5.  Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region.

Authors:  M Robert-Guroff; S H Weiss; J A Giron; A M Jennings; H M Ginzburg; I B Margolis; W A Blattner; R C Gallo
Journal:  JAMA       Date:  1986-06-13       Impact factor: 56.272

6.  Detection of acquired immunodeficiency syndrome (AIDS) retrovirus antibody by lymphadenopathy-associated virus (LAV) enzyme immunoassay in low- and high-risk populations.

Authors:  M V Ragni; J H Lewis; M Bracken; R Toth; J Stokes; D O Steffensen
Journal:  Transfusion       Date:  1986 May-Jun       Impact factor: 3.157

7.  Acquired immunodeficiency syndrome (AIDS) in an economically disadvantaged population.

Authors:  S Maayan; G P Wormser; D Hewlett; S N Miller; F P Duncanson; A Rodriguez; E N Perla; B Koppel; E E Rieber
Journal:  Arch Intern Med       Date:  1985-09

8.  Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco.

Authors:  R E Chaisson; A R Moss; R Onishi; D Osmond; J R Carlson
Journal:  Am J Public Health       Date:  1987-02       Impact factor: 9.308

9.  The epidemic of acquired immunodeficiency syndrome (AIDS) and suggestions for its control in drug abusers.

Authors:  M Marmor; D C Des Jarlais; S R Friedman; M Lyden; W el-Sadr
Journal:  J Subst Abuse Treat       Date:  1984
  9 in total
  19 in total

1.  Explaining the geographical variation of HIV among injection drug users in the United States.

Authors:  D Ciccarone; P Bourgois
Journal:  Subst Use Misuse       Date:  2003-12       Impact factor: 2.164

2.  Drug prevention: The past as the future?

Authors:  C G Leukefeld; R R Clayton
Journal:  J Prim Prev       Date:  1994-09

3.  Variables influencing condom use among intravenous drug users.

Authors:  S Magura; J L Shapiro; Q Siddiqi; D S Lipton
Journal:  Am J Public Health       Date:  1990-01       Impact factor: 9.308

4.  HIV seroprevalence among male IVDUs in Houston, Texas.

Authors:  M L Williams
Journal:  Am J Public Health       Date:  1990-12       Impact factor: 9.308

5.  HIV seropositivity and IVDUs: ethnic/gender comparisons.

Authors:  D K Lewis; J K Watters
Journal:  Am J Public Health       Date:  1988-11       Impact factor: 9.308

6.  Needle sharing among IVDUs at risk for AIDS.

Authors:  D C Des Jarlais; S R Friedman
Journal:  Am J Public Health       Date:  1988-11       Impact factor: 9.308

7.  Racial/ethnic differences in the risk of AIDS in the United States.

Authors:  R M Selik; K G Castro; M Pappaioanou
Journal:  Am J Public Health       Date:  1988-12       Impact factor: 9.308

8.  HIV seroprevalence in intravenous drug users: Los Angeles, California, 1986.

Authors:  L Mascola; L Lieb; K A Iwakoshi; D McAllister; T Siminowski; M Giles; G Run; S L Fannin; I H Strantz
Journal:  Am J Public Health       Date:  1989-01       Impact factor: 9.308

9.  [Is there an increased risk of infection in trauma surgery emergency admission for medial personnel by unknown HIV-positive patient status?].

Authors:  G Mathiak; J V Wening; G Fröschle; K H Jungbluth
Journal:  Unfallchirurgie       Date:  1995-10

Review 10.  AIDS-related behavioral research and nursing.

Authors:  A Skinner; L Walls; L S Brown
Journal:  J Natl Med Assoc       Date:  1991-07       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.